VANCOUVER, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce an update on our recent product line addition of three new vaporizers. Currently, the VB-1, VB-2, CA-2 and the KB-1 have now been made available for purchase through our website Abattis.com. Our vaporizers feature a 510 threaded battery that can be used with any third-party vaporizer cartridge.
The “VB-1” is equipped with a 280mAh battery and fires automatically, activating its battery based on airflow. The unit features an ultra-slim and discreet design and a working voltage of 3.3V to 4.2V. The VB-1 includes a universal USB attachment which makes it easy to recharge.
The “VB-2” uses a compact 350mAh variable voltage battery, designed with built-in protections against short-circuiting and overheating, and features a conventional preheating function that the user activates with two clicks of a button. The unit uses working voltages of 3.4V, 3.7V and 4.0V and includes a USB attachment for recharging.
The “CA-2” cartridge is built with a top-quality ceramic & stainless-steel heating system. The embedded stainless-steel wire in the multi-holed ceramic bar is superior to most in the market. This results in a highly efficient, healthier, pure flavor.
The “KB-1” features an innovative battery designed to look like a luxury car’s key fob, which is ideal for those looking for a discreet device or for use during travel. The cutting-edge device is equipped with a 510-threaded connection that can be closed to house attachments and features a built-in USB charging cable, a long-lasting embedded 350mAh lithium ion battery, a key ring and an LED light indicator. The unit supports most attachments rated as low as 1.2 ohms and operates at 3.7V.
Details on Global Vaporizer Markets:
The “Vapor Products Market (E-vapor and Heat-not-Burn Devices) – Global Outlook and Forecast 2018-2023” report states, “The growing global health awareness and technological developments aiding safer smoking is driving the global vapor products (e-vapor and heat-not-burn [HnB] devices) market and is expected to cross $43 billion by 2023, growing at an impressive CAGR of over 15% over 2017-2023.”
“The vapor products market is witnessing an increase in desire among end-users globally to quit smoking because of the increasing number of deaths caused by smoking-related cancer, respiratory diseases, and heart diseases. These factors are primarily contributing to the decline of the global sales volume of traditional cigarettes over the last few years. This trend, coupled with continuous innovations in e-vapor and HnB devices, is prompting large tobacco companies such as Altria Group, Imperial Tobacco, Philip Morris International, and British American Tobacco to shift their focus toward the development of these products,” the “Global Outlook and Forecast 2018-2023” report states.
The global vapor products (e-vapor and heat-not-burn [HnB] Devices) market is expected to grow at a faster pace over the next few years. Online sales are expected to increase significantly due to availability of more choices to consumers than retail stores.
“The cannabis vaporizer market is growing at a tremendous rate and gaining popularity worldwide. Abattis is excited to introduce our next generation vapor products to consumers and capitalize on the revolution towards the healthier consumption of extracts,” stated Rob Abenante, President and CEO of Abattis Bioceuticals Corp.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP.
Robert Abenante, President & CEO
For more information, please visit the Company’s website at: www.abattis.com
For inquiries please contact (808) 650-3007 or at firstname.lastname@example.org. Abattis IR is managed by Canada One Communications Inc.
About Canada One Communications Inc.
Canada One is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the global vaporizer market, the success of the marketing and sales of Abattis Vaporizers, and anticipation of the vaporizer market gaining worldwide popularity. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.